Earnings (Loss) Per Common Share (EPS) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings (Loss) Per Common Share (EPS) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings (Loss) Per Common Share (EPS) | 16. Earnings (Loss) Per Common Share (EPS)
The computations of basic and diluted EPS for the years ended were as follows:
For the year ended December 31, 2025, the Company had unexercised stock options of 168,570 that were anti-dilutive. For the year ended December 31, 2024, the Company had unexercised stock options of 288,570 and warrants to purchase 150,000 shares of common stock, outstanding, that were anti-dilutive. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||